Drug Profile
Adalimumab biosimilar - Alphamab
Alternative Names: KN 002Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Alphamab
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 12 Jul 2019 Discontinued - Phase-I for Rheumatoid arthritis in China (SC) (Alphamab pipeline, July 2019)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in China (SC, Injection)
- 05 May 2015 Phase-I clinical trials in Rheumatoid arthritis in China before May 2015 (SC)